<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01702909</url>
  </required_header>
  <id_info>
    <org_study_id>12-08</org_study_id>
    <nct_id>NCT01702909</nct_id>
  </id_info>
  <brief_title>Interleukin-2 in Metastatic Kidney Cancer</brief_title>
  <official_title>Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Kidney Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used&#xD;
      in this study will help increase tumor shrinkage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II study, the IL-2 schedule (daily IL-2 for 5 days (per week) every 3 weeks)&#xD;
      will be tested in a cohort of kidney cancer patients to attempt to determine the response&#xD;
      rate, median duration of response, and median survival. The dose intensity of this schedule&#xD;
      would allow a patient treated on this regimen to achieve the target threshold (&gt; 1440 million&#xD;
      IU/m2/year).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI Decision&#xD;
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Response Using RECIST Criteria</measure>
    <time_frame>Measured until Disease Progression or death from any cause up to 2 year</time_frame>
    <description>Radiographic studies to evaluate for response were done after every 2 cycles (6 weeks) until disease progression or death from any cause up to 2 years. Standard RECIST response criteria were utilized. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response Rate (ORR) = 100%(CR + PR/total number of patients receiving Interleukin-2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Duration of Response</measure>
    <time_frame>Measured from first response until Disease Progression or death from any cause up to 2 years</time_frame>
    <description>Duration of response is calculated as the time (months) from the date at which response is first observed (per standard Response Evaluation Criteria In Solid Tumors [RECIST] to the date of first observed disease progression or date of death from any cause, whichever came first, assessed up to 2 years. The actual date of tumor assessments was used for this calculation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Survival</measure>
    <time_frame>measured from date of first dose until date of death</time_frame>
    <description>from time of study entry until death</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Renal Cell Cancer Metastatic</condition>
  <condition>Kidney Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Interleukin-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interleukin-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>Interleukin-2</description>
    <arm_group_label>Interleukin-2</arm_group_label>
    <other_name>IL2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have a histologic diagnosis of metastatic kidney cancer. Patients may&#xD;
             have received prior systemic therapy or may be previously untreated&#xD;
&#xD;
          2. Patients must have bi-dimensional measurable disease on physical exam or radiologic&#xD;
             studies.&#xD;
&#xD;
          3. ECOG performance status of 0 or 1 and estimated survival of at least 3 months.&#xD;
&#xD;
          4. White blood count of &gt; 3500/mm3, platelet count &gt; 100,000/mm3, hemoglobin &gt; 9.0 gm/dl;&#xD;
             bilirubin, ALT, AST &lt; 3 x upper limit of normal; serum creatinine &lt; 2.0 mg/dl.&#xD;
&#xD;
          5. Patients must undergo a low-level cardiac stress test as a screen for possible&#xD;
             atherosclerotic heart disease. Patients with a positive stress test would be excluded&#xD;
             from this trial.&#xD;
&#xD;
          6. Patients with elevated temperatures &gt; 100.5 F must have sources of occult infection&#xD;
             excluded.&#xD;
&#xD;
          7. Patients must be felt to have recovered from effects of prior therapy, such as &gt; 2&#xD;
             weeks after prior chemotherapy.&#xD;
&#xD;
          8. Patient consent must be obtained prior to entrance onto study.&#xD;
&#xD;
          9. Women of childbearing potential must have a negative pregnancy test and must take&#xD;
             adequate precautions to prevent pregnancy during treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Medical illness requiring corticosteroids or other immunosuppressive agents (such as&#xD;
             cyclosporin or methotrexate.&#xD;
&#xD;
          2. Autoimmune disease such as inflammatory arthritis which could be exacerbated by&#xD;
             immune-based therapy.&#xD;
&#xD;
          3. Prior history of psychiatric disorder which could be exacerbated by interleukin-2.&#xD;
&#xD;
          4. Lactation or pregnancy.&#xD;
&#xD;
          5. Evidence of significant cardiovascular disease including history of recent (&lt; 6 months&#xD;
             prior) myocardial infarction, congestive heart failure, primary cardiac arrhythmias&#xD;
             (not due to electrolyte disorder or drug toxicity, for example) beyond occasional&#xD;
             PVC's, angina, positive low-level stress test, or cerebrovascular accident.&#xD;
&#xD;
          6. Current brain metastasis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Quan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Regional Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Regional Medical Center, Inc</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>October 4, 2012</study_first_submitted>
  <study_first_submitted_qc>October 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2012</study_first_posted>
  <results_first_submitted>August 14, 2017</results_first_submitted>
  <results_first_submitted_qc>September 23, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 27, 2017</results_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Renal Cell</keyword>
  <keyword>Metastatic Kidney Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Interleukin-2</title>
          <description>Interleukin 2 (IL-2) is naturally produced by the body to help fight infection and prevent autoimmune diseases. In cancer treatment, IL-2 is designed to target adaptive immune cells, such as T-cells and B-cells, to respond to tumors. IL-2 may help the body produce antigen-fighting T-cells and stimulate B-cells to produce more antibodies.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Number of Participants</title>
          <description>Treated with Interleukin-2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="54" upper_limit="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Response Using RECIST Criteria</title>
        <description>Radiographic studies to evaluate for response were done after every 2 cycles (6 weeks) until disease progression or death from any cause up to 2 years. Standard RECIST response criteria were utilized. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response Rate (ORR) = 100%(CR + PR/total number of patients receiving Interleukin-2).</description>
        <time_frame>Measured until Disease Progression or death from any cause up to 2 year</time_frame>
        <population>No data was collected</population>
        <group_list>
          <group group_id="O1">
            <title>Response Rate</title>
            <description>Percentage of Patients Responding to Interleukin-2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response Using RECIST Criteria</title>
          <description>Radiographic studies to evaluate for response were done after every 2 cycles (6 weeks) until disease progression or death from any cause up to 2 years. Standard RECIST response criteria were utilized. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response Rate (ORR) = 100%(CR + PR/total number of patients receiving Interleukin-2).</description>
          <population>No data was collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Duration of Response</title>
        <description>Duration of response is calculated as the time (months) from the date at which response is first observed (per standard Response Evaluation Criteria In Solid Tumors [RECIST] to the date of first observed disease progression or date of death from any cause, whichever came first, assessed up to 2 years. The actual date of tumor assessments was used for this calculation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of one or more new lesions.</description>
        <time_frame>Measured from first response until Disease Progression or death from any cause up to 2 years</time_frame>
        <population>There are no data recordings for this study. The study was terminated and the investigator is no longer related to the site. There is no additional information to provide.</population>
        <group_list>
          <group group_id="O1">
            <title>Response Rate</title>
            <description>Percentage of Patients Responding to Interleukin-2</description>
          </group>
        </group_list>
        <measure>
          <title>Median Duration of Response</title>
          <description>Duration of response is calculated as the time (months) from the date at which response is first observed (per standard Response Evaluation Criteria In Solid Tumors [RECIST] to the date of first observed disease progression or date of death from any cause, whichever came first, assessed up to 2 years. The actual date of tumor assessments was used for this calculation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of one or more new lesions.</description>
          <population>There are no data recordings for this study. The study was terminated and the investigator is no longer related to the site. There is no additional information to provide.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Survival</title>
        <description>from time of study entry until death</description>
        <time_frame>measured from date of first dose until date of death</time_frame>
        <population>There are no data recordings for this study. The study was terminated and the investigator is no longer related to the site. There is no additional information to provide.</population>
        <group_list>
          <group group_id="O1">
            <title>Response Rate</title>
            <description>Percentage of Patients Responding to Interleukin-2</description>
          </group>
        </group_list>
        <measure>
          <title>Median Survival</title>
          <description>from time of study entry until death</description>
          <population>There are no data recordings for this study. The study was terminated and the investigator is no longer related to the site. There is no additional information to provide.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, approximately 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adverse Events</title>
          <description>Patients receiving Interleukin-2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/emesis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Catarrhal/sinus symptoms</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthalgia/myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jessica L. Coats</name_or_title>
      <organization>Western Regional Medical Center</organization>
      <phone>623-207-3899</phone>
      <email>jessica.coats@ctca-hope.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01702909
org study id: 12-08
nct id: NCT01702909
lead sponsor: 
has dmc: No
The purpose of this study is to determine whether Interleukin-2 at the dose and schedule used
      in this study will help increase tumor shrinkage.
In this phase II study, the IL-2 schedule (daily IL-2 for 5 days (per week) every 3 weeks)
      will be tested in a cohort of kidney cancer patients to attempt to determine the response
      rate, median duration of response, and median survival. The dose intensity of this schedule
      would allow a patient treated on this regimen to achieve the target threshold (> 1440 million
      IU/m2/year).
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Number of Participants With Response Using RECIST Criteria
time frame: Measured until Disease Progression or death from any cause up to 2 year
description: Radiographic studies to evaluate for response were done after every 2 cycles (6 weeks) until disease progression or death from any cause up to 2 years. Standard RECIST response criteria were utilized. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT scan: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response Rate (ORR) = 100%(CR + PR/total number of patients receiving Interleukin-2).
measure: Median Duration of Response
time frame: Measured from first response until Disease Progression or death from any cause up to 2 years
description: Duration of response is calculated as the time (months) from the date at which response is first observed (per standard Response Evaluation Criteria In Solid Tumors [RECIST] to the date of first observed disease progression or date of death from any cause, whichever came first, assessed up to 2 years. The actual date of tumor assessments was used for this calculation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of one or more new lesions.
measure: Median Survival
time frame: measured from date of first dose until date of death
description: from time of study entry until death
arm group label: Interleukin-2
arm group type: Experimental
description: Interleukin-2
intervention type: Drug
intervention name: Interleukin-2
description: Interleukin-2
arm group label: Interleukin-2
other name: IL2
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Walter Quan, MD
role: Principal Investigator
affiliation: Western Regional Medical Center
facility: 
country: United States
responsible party type: Sponsor
mesh term: Carcinoma, Renal Cell
mesh term: Kidney Neoplasms
mesh term: Neoplasms
mesh term: Interleukin-2
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 